• Biofrontera published its 2025 annual report, highlighting continued Ameluz growth in core European markets.
• Ameluz sales in Germany rose more than 20% for third straight year, supporting market leadership in Germany, Spain, UK.
• Group completed major restructuring with Biofrontera Inc., transferring US-related assets, staff, approvals, IP.
• Deal terms include Biofrontera taking a 10% post-money stake in Biofrontera Inc. plus earn-out of 12%-15% of Ameluz US net sales through 2043.
• Biofrontera exited EU lamp manufacturing, shifting production processes to Biofrontera Inc. group, streamlining European cost base.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera AG published the original content used to generate this news brief on April 17, 2026, and is solely responsible for the information contained therein.